SOURCE: Zivo Bioscience, Inc.

December 02, 2014 11:23 ET

ZIVO Bioscience and WellMetris Subsidiary Announce Pilot Program and Pending Order for Point of Care Wellness Test

KEEGO HARBOR, MI--(Marketwired - Dec 2, 2014) -  ZIVO Bioscience, Inc. (OTCQB: ZIVO), formerly Health Enhancement Products, Inc., and its WellMetris subsidiary announced today that Trion Solutions, Inc., a leading human resources company with over 1,000 clients, and 15,000 employees, has committed to a pilot program to evaluate the health and economic benefits offered by the Company's proprietary Wellness Profile testing platform. Five-hundred Trion employees will initially take the test, which measures several key areas of metabolic health, including lipid peroxidation, inflammation, hydration and nitrite/nitrate balance, among others.

Based on the price/performance metrics projected by WellMetris, Trion Solutions will underwrite a program to test a much larger group of eligible individuals and dependents. Craig A. Vanderburg, Chief Operating Officer of Trion Solutions, stated, "We are excited about using the WellMetris test to establish a baseline of health for our employees. It's a potential breakthrough that can provide valuable information to the individuals who take the test and the wellness consultants or early intervention providers tasked with improving employee health."

The test is designed to uncover pre-conditions favorable to the onset of disease or impairment usually brought on by unhealthy or stressful lifestyle choices, focusing primarily on the "The Big Four" -- stroke, heart disease, diabetes and cancer. The results can help employers or insurers better focus early intervention or prevention programs to head off future problems. The WellMetris Profile can be administered in office, retail, shop floor or clinic settings, providing results in three minutes or less. The Company now has seven patents in application and is currently negotiating commercial relationships.

Andrew Dahl, CEO of ZIVO Bioscience, the parent company of WellMetris, commented: "We're very pleased to launch this pilot program with Trion Solutions. The fact that a company of this size and stature values the benefits of our test and monitoring program is significant. I believe this to be the first of many companies that will use our unique point-of-care testing platform to determine the overall health of their employees and subsequently focus their early intervention and preventative health programs to achieve healthy outcomes and cost savings."

The Affordable Care Act (ACA) represents other potentially significant opportunities for WellMetris. Language in the ACA calls for establishing a 'baseline' of wellness for managed populations and routine screening after pre-clinical intervention, such as weight loss programs, smoking cessation, drug rehab, etc. The Well Metris Profile test doesn't look for the presence of drugs, alcohol or tobacco. Rather, it looks for the downstream consequences in the overall health of an individual. The test provides an objective and scientifically sound assessment of the impact of unhealthy lifestyle choices, which can also include obesity, lack of exercise or sleep, and similar behaviors. This may also apply to Medicaid recipients. The test and its innovative data distribution and analysis back-end establishes a protocol for intervention which could place WellMetris at the forefront of pre-clinical screening programs for millions of Americans.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune modulation.

About WellMetris, LLC

WellMetris, LLC, a wholly-owned subsidiary of ZIVO Bioscience, Inc. develops and markets metabolic testing technologies for humans and animals -- a biomed/IT convergence platform based on its proprietary chemistry, software and cloud-based data warehousing. The Company is currently positioning its first product for market introduction.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.